Utilizing the company’s unique technology platform, Glycotope has developed a mature pipeline of first-in-class and best-in-class biopharmaceuticals. Three oncology products are currently in advanced clinical development.
With the combined advantages of optimized sialylation, galactosylation, fucosylation, branching and absence of non-human sugar structures, GEX® products may result in higher efficacy, fewer side effects and/or broader coverage of patients and indications.
Glycotope is currently seeking development and commercialization partners for several of its late-stage assets.
Gatipotuzumab (previously known as PankoMab-GEX®) – Glycotope’s first-in-class antibody against the tumor-specific carbohydrate-protein epitope TA-MUC1 that showed a good safety profile and anti-tumor activity in a single agent Phase 1 study. The compound is currently in a Phase 2 study as maintenance therapy for recurrent ovarian cancer.
Tomuzotuximab (previously known as CetuGEX®) – a novel glyco-optimized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) that showed promising therapeutic activity in a single agent Phase 1 dose escalation study in patients with various solid tumors. The compound is currently in a Phase 2b study in squamous cell carcinomas of the head and neck.
TrasGEX® – a novel glyco-optimized anti-Her2 receptor mAb that has been tested in a Phase 1/2a clinical trials with in patients with Her-2 positive tumors whose disease progressed following treatment with standard therapies.
FSH-GEX® – the first fully human glycosylated FSH (follicle-stimulating hormone) that has successfully completed a Phase II study.